INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to gradual loss of memory, reasoning, orientation, and judgment. The confirmed diagnosis of AD requires the presence of two major neuropathological lesions: neurofibrillary tangles and b-amyloid deposition in brain. A significant portion of AD cases are genetic in etiology (for review see Tanzi et al., 1994; Wasco & Tanzi, 1995) and are termed familial Alzheimer's disease (FAD). FAD is genetically heterogeneous and in a subset of kindreds is inherited as an autosomal dominant disorder with nearly 100% penetrance. Phenotypically, FAD can be categorized according to age of onset using either 65 years or, more commonly, 60 years for the cutoff between early-onset and lateonset FAD. Genetic analyses have led to the identification of ''causative'' gene defects in three early-onset (,60 year) FAD genes located on chromosomes 1, 14, and 21, as well as an inherited ''risk factor'' for late-onset FAD (.60 years) on chromosome 19.
b-Amyloid is present in the AD brain in the form of senile plaques and cerebral blood vessel deposits. A wealth of data suggests a central and essential role for the deposition of b-amyloid along with the generation and aggregation of its major component, the Ab peptide (Glenner & Wong, 1984) , in the etiology and pathogenesis of AD (for review see Wasco & Tanzi, 1995) . The deposition of Ab or specific forms of the peptide appears to be the common pathogenic event which ties together the pathogenetic mechanisms of the various genetic defects leading to AD neuropathogenesis. Augmented deposition of b-amyloid is observed in middle-aged patients with Down Syndrome (DS; trisomy 21), most likely owing to the inheritance of three copies of chromosome 21 which contains the gene for the amyloid b-protein precursor (APP; Tanzi et al., 1987) . Six different mutations have been identified in the APP gene (Goate et al., 1991; Levy et al., 1990; Murrell et al., 1991; Chartier-Harlin et al., 1991; Hendriks et al., 1992; Mullen et al., 1992) , all lying near or within the Ab domain. These mutations have been shown to nearly 100% penetrant and can thus be considered ''deterministic'' for early-onset FAD. Overall, the APP mutations are responsible for only a small proportion (roughly 2%) of all published cases of FAD (Tanzi et al., 1992) and roughly 5-7% of early-onset FAD. Transgenic mice expressing the APP717V = F mutation have been showed to produce b-amyloid deposits in the form of classical senile plaques accompanied by neuronal and synaptic loss and gliosis (Games et al., 1995) supporting the pathogenicity of the FAD APP mutations. The majority of early-onset FAD cases have been associated with mutations in two novel genes which have been termed presenilin 1 (PS1) on chromosome 14 and presenilin 2 (PS2) on chromosome 1 (Sherrington et al., 1995; Levy-Lehad et al., 1995; Rogaev et al., 1995) . Plasma and fibroblasts from patients as well as at-risk carriers harboring mutations in the presenilins have been shown to contain increased amounts of the longer, more amyloidogenic version of the Ab peptide referred to as Ab1-42 or Abx-42 (Scheuner et al., 1996) . The final piece of genetic evidence implicating a central and essential role for Ab production, aggregation, and deposition in
